Objective: Pedal (inframalleolar) bypass is a long-standing therapy for tibial arterial disease in patients with ischemic tissue loss. Endovascular tibial intervention is an appealing alternative with lower risks of perioperative mortality or complications. Our objective was to compare the effectiveness of these two treatment modalities with respect to patency and limb-related clinical outcomes.
Critical limb ischemia carries a high risk of amputation. 1 In patients with tissue loss secondary to peripheral arterial disease, prompt revascularization is necessary to maximize the chances of wound healing and limb salvage. 2, 3 Historically, open surgical bypass has been the standard of care for lower extremity revascularization. However, endovascular therapies have evolved considerably and are becoming first-line therapies in many situations, with good clinical outcomes in patients with critical limb ischemia. [3] [4] [5] Patients with infrapopliteal arterial disease are more likely to have coronary artery disease. These patients have higher mortality rates compared with those with more proximal disease, 6 and thus lower risk endovascular therapies are particularly attractive in this population of patients. If endovascular therapy provides acceptable limb-related outcomes, it would be a favorable treatment strategy in such patients.
A number of studies have compared outcomes between patients undergoing bypass and those undergoing endovascular intervention, although none have focused specifically on tibial disease. 2, 7 The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial, the only multicenter, randomized trial to compare these treatment modalities head to head, found no significant difference in amputation-free survival between bypassfirst and endovascular-first treatment strategies. 8 Few studies, however, have specifically compared outcomes The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a conflict of interest.
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Copyright in those undergoing pedal bypass with those undergoing endovascular tibial intervention. [9] [10] [11] In particular, successful wound healing, which is the indication for many of these procedures, is infrequently studied as a clinical outcome. Our objective was to compare pedal bypass and endovascular tibial intervention, with respect to both clinical and patency outcomes, in a contemporary cohort of patients with tibial arterial disease and ischemic tissue loss.
METHODS
This study was approved by the University of Pittsburgh Medical Center Institutional Review Board. The requirement for informed consent was waived because of the retrospective nature of our work. Patients were included if they presented to our institution between 2006 and 2013 with infrapopliteal arterial occlusive disease and ischemic foot wounds and underwent either surgical bypass to an inframalleolar target (the bypass group) or endovascular intervention to one or more tibial vessels (the endovascular group). Patients with concomitant disease more proximally were included to encompass a more real-world population of patients. Patients were excluded if the index wound or any additional wound was located above the ankle, no follow-up data were available, or the index procedure was performed at another institution.
Data were collected from the electronic medical record on the patients' demographics, comorbidities, smoking history, and prior medications. Wounds were classified retrospectively by the Wound, Ischemia, foot Infection (WIfI) criteria. 12 When available, more granular wound data were abstracted from the record. Details of the revascularization procedure, timing and number of subsequent procedures, and postoperative outcomes and complications were reviewed. Data were compiled in Excel (Microsoft, Redmond, Wash). The primary outcome was wound healing, defined as complete healing of the index wound documented at a subsequent inpatient or outpatient visit. If a minor amputation was performed at the time of revascularization, the amputation incision was considered to be the index wound. Wound care was coordinated in all patients by the vascular surgeon, who would evaluate wounds in the office on a biweekly basis and determine the optimal local wound care strategy alone or in conjunction with a podiatrist. Dressing changes and other aspects of wound care may have been provided by the patient or family members, visiting nurses, or staff at a skilled nursing facility as appropriate for each patient's individual needs. Secondary outcomes included 30-day mortality and complication rates as well as long-term death, major amputation, primary patency, primary assisted patency, and secondary patency rates. Patency in the bypass group refers to patency of the entire bypass graft; patency in endovascular interventions refers to patency in the treated segment of each vessel.
Stata 15.0 (StataCorp LP, College Station, Tex) was used for all statistical analysis. Baseline characteristics were compared using Student t-test or Fisher exact test for continuous or categorical data, respectively. Where appropriate, nonparametric tests were used for data with skewed distributions. The 30-day outcomes were analyzed by logistic regression analysis. Longer term outcomes were depicted by Kaplan-Meier curves. Wound healing was shown only up to 12 months as healing beyond this time point was not thought to be reflective of the index procedure; all other outcomes are shown up to 5 years. The log-rank test was used to identify differences between the bypass and endovascular groups. Cox proportional hazards models were used to identify risk factors for wound healing, the primary outcome. After identification of univariate risk factors, those that were found to be significant or nearly significant were included in a multivariate model using a backward stepwise selection process. For all statistical tests, a P value of <.05 was considered to be statistically significant. For all Kaplan-Meier curves, standard error was <10% for each group at every time point shown.
RESULTS
We identified 417 patients who underwent revascularization for infrapopliteal disease in the setting of an ischemic foot ulceration. Among these patients, 105 underwent bypass (all of which were to a target below the ankle) and 312 underwent endovascular tibial intervention. Mean follow-up was 25.0 months in the bypass group and 20.2 months in the endovascular group (P ¼ .08). Baseline characteristics were mostly similar between the two groups (Table I) . Patients undergoing bypass tended to be younger with lower rates of hyperlipidemia and a history of stroke or other neurovascular symptoms, with trends toward lower rates of chronic obstructive pulmonary disease and renal impairment. There was also a greater proportion of current smokers in the bypass group. When classified by the WIfI criteria (Table II) , the wounds were found to be more severe in the bypass group (P ¼ .047). There was no difference in the ischemia or foot infection components of the WIfI score.
ARTICLE HIGHLIGHTS
Operative details for the bypass patients are detailed in Table III . The most common inflow was the below-knee popliteal artery, and the most common target was the dorsalis pedis artery. In 70.5% of cases, a singlesegment great saphenous vein was used as a conduit; nearly all of the remainder were performed using alternative autologous vein. In 3.8% of bypass patients, a concomitant open or endovascular intervention was performed more proximally. Details for the endovascular patients are detailed in Table IV . All cases were performed by antegrade access to the tibial vessels through the contralateral or ipsilateral common femoral artery. The anterior tibial, posterior tibial, or peroneal artery was considered treated if the intervention was successful in establishing in-line flow to the dorsalis pedis, inframalleolar posterior tibial artery, or distal peroneal artery, respectively. Multiple tibial vessels were treated in the same setting in 31.1% of patients. Balloon angioplasty was the primary endovascular treatment modality, with atherectomy and stenting used less frequently. Stenting was rare and typically reserved for flow-limiting dissections after balloon angioplasty. In 46.2% of endovascular patients, a concomitant intervention was performed on a more proximal vessel in the ipsilateral extremity. The iliac, superficial femoral, and popliteal arteries were treated in 6.2%, 58.4%, and 77.0% of patients, respectively.
Median length of stay after the index procedure was significantly longer in bypass patients at 7 days vs 3 days (P < .0001). Bypass patients were also more likely to be discharged to a nursing facility rather than to home (P < .001). There was no difference in 30-day mortality between groups (P ¼ .31), but bypass patients were more likely to experience a myocardial infarction (P ¼ .03) or wound complication (P < .001) postoperatively. There were no differences in rates of other postprocedure complications between the two groups (Table V) .
Complete wound healing at any point during follow-up was documented in 45.8% of patients, with no difference between treatment groups (P ¼ .49). Fig 1 shows rates of successful wound healing stratified by treatment modality. In our cohort, wound healing was superior in the endovascular group compared with the bypass group (P ¼ .02). At 6 months, the Kaplan-Meier estimated rate of wound healing was 22.4% after bypass and 29.0% after endovascular intervention (Table VI) . On univariate analysis, endovascular intervention was associated with an improved rate of wound healing (hazard ratio [HR], 1.45; Kaplan-Meier curves for the outcomes of death and major amputation are shown in Fig 2. The bypass group had significantly improved survival compared with the endovascular group (P < .0001; Fig 2, A) . Compared with bypass, endovascular intervention was associated with increased long-term mortality risk (HR, 2.32; 95% CI, 1.58-3.41; P < .001). Freedom from major amputation (Fig 2, B) did not differ between the two groups (P ¼ .42). Major amputation-free survival curves (Fig 2, C) were similar to those for survival and showed a significant difference between groups (P ¼ .0002). As with mortality, endovascular intervention was associated with a higher rate of major amputation or death (HR, 1.86; 95% CI, 1.34-2.59; P < .001). The 1-year and 5-year clinical outcome rates are summarized in Table VI . Categorical variables are presented as number (%). Continuous variables are presented as median (interquartile range).
Fig 1.
Kaplan-Meier curves depicting wound healing, stratified by treatment modality.
Kaplan-Meier curves of patency outcomes are shown in Fig 3. Primary patency (P ¼ .002) and primary assisted patency (P < .0001) were superior in the bypass group, with a similar but nonsignificant trend in secondary patency (P ¼ .13). On univariate analysis, endovascular intervention was associated with greater loss of primary patency (HR, 1.63; 95% CI, 1.19-2.23; P ¼ .002) and primary assisted patency (HR, 2.72; 95% CI, 1.76-4.20; P < .001) but not secondary patency (HR, 1.43; 95% CI, 0.90-2.28; P ¼ .13). Patency rates at 1 year and 5 years are summarized in Table VI. A subgroup analysis was performed on patients with isolated infrapopliteal disease. All patients who underwent a concomitant procedure more proximally and bypass patients with suprageniculate inflow were excluded for this subgroup analysis. The remaining cohort consisted of 239 patients, with 71 undergoing bypass and 168 undergoing endovascular intervention. In the new cohort, endovascular intervention continued to be associated with improved wound healing (HR, 1.63; 95% CI, 1.06-2.51; P ¼ .03). The multivariate model identified one new predictor, presence of a cancer diagnosis, that impeded wound healing (HR, 0.47; 95% CI, 0.24-0.92; P ¼ .03). In the new multivariate model, endovascular intervention persisted as a factor associated with improved healing (HR, 1.74; 95% CI, 1.12-2.70; P ¼ .01). As in the original cohort, endovascular intervention was associated with decreased survival (P ¼ .004) and amputation-free survival (P ¼ .007) but equivalent major amputation rates (P ¼ .16). Patency rates also mirrored those of the original cohort, with improved primary patency (P ¼ .03) and primary assisted patency (P ¼ .004) after bypass and a nonsignificant trend toward improved secondary patency (P ¼ .27).
DISCUSSION
Endovascular tibial intervention has gained significant interest in recent years. The objective of this study was to evaluate whether its effectiveness in patients with extensive tibial disease is similar to that of bypass to a pedal target, specifically with regard to limb-related clinical outcomes rather than patency outcomes alone. We chose specifically to study the highest risk group, those with ischemic tissue loss, and defined successful healing of the index wound as our primary end point. We found in our cohort that whereas mortality rates were similar in the perioperative period, bypass was associated with a longer hospital stay, higher rate of discharge to nursing facility, and more cardiac and wound complications compared with endovascular intervention. As a procedure with lower perioperative risk than surgical bypass, endovascular tibial intervention is certainly appealing in a population of patients known to suffer from high rates of diabetes mellitus, coronary artery disease, and renal impairment. 13, 14 We found that the wound healing rate in this cohort was poor overall, with approximately one in four wounds healing successfully at 6 months. Wound healing rates vary widely in the literature, highlighting a large variation in practice patterns and reporting definitions, but generally reflect a poor ability to heal wounds in patients with tibial disease. 6, [15] [16] [17] The reasons for this are likely to be multifactorial; even with appropriate revascularization and a satisfactory hemodynamic result, concomitant issues such as diabetes, renal impairment, and poor nutritional status can limit the success of wound healing. As a tertiary care center, our population of patients is characterized by greater comorbidity burden and overall frailty compared with a typical vascular surgery practice, and our relatively low wound healing rates probably reflect this difference. We noted that endovascular intervention was associated with improved wound healing in our cohort. It is notable that the baseline WIfI wound scores were slightly more severe in the bypass group, and this discrepancy in healing rates may be indicative of selection bias; nevertheless, it appears that an endovascular approach is not detrimental to wound healing. In examining other clinical outcomes, we found that major amputation rates were similar between the two groups and <20% overall. The mortality rate was significantly higher in the endovascular group; the composite outcome of amputation-free survival reflected the same difference. As with the improved wound healing rates, this difference is likely to be due to selection bias, as patients who are offered a distal bypass are inherently a different group of patients than those offered an endovascular intervention. Data on cause of death were not readily available or believed to be accurate enough to report. The 50% 5-year mortality rate even among patients offered a bypass operation highlights the high comorbidity burden in patients with tibial arterial disease. Surgical bypass clearly proved to be the more durable treatment choice with respect to patency outcomes. The primary and primary assisted patency rates after endovascular intervention were far lower than those after bypass, and as seen in our clinical practice, reinterventions are commonly required after tibial interventions. The tibial vessels are small and typically heavily calcified and are prone to restenosis after treatment. However, we found that secondary patency was comparable between the two groups. This may explain the comparable clinical outcomes, although at the cost of a greater reintervention rate and need for closer follow-up in the endovascular patients.
Steady improvements in endovascular technologies may allow us to eventually see improved durability in the tibial space. In the time period we studied, uncoated balloon angioplasty was almost universally the preferred choice of endovascular treatment modality. Newer treatment options, most notably drug-coated balloons and drug-eluting stents, have shown great promise in the femoropopliteal arteries. [18] [19] [20] Their effectiveness in the tibial vessels, particularly with respect to wound healing, is not well studied, although wound healing rates exceeding 80% have been described with drug-eluting tibial stents. 17, 21 There will certainly always be a role for surgical bypass, particularly in younger, lower risk patients with favorable anatomy and available conduit. However, in appropriately selected patients who are poor surgical candidates or lack good-quality conduit for a bypass, endovascular therapies will become an increasingly viable option for wound healing and limb salvage.
There are a number of limitations to this retrospective study. There is likely to be selection bias, with the bypass and endovascular groups being different with respect to baseline comorbidities and risk factors. In particular, we noted that more extensive wounds may have been preferentially treated with bypass. It is also possible that a more severe anatomic disease burden would predispose a patient to bypass. To account for this, we performed a subgroup analysis with only those patients who had isolated infrapopliteal disease and found that our results were nearly identical to those of the original cohort. In addition, whereas we were able to score wounds by the WIfI criteria, wound data were not granular enough to study these wounds in more detail. In particular, exact size, depth of tissue involvement, and location on the foot were not always accurately documented. This limited our ability to account for differences in wound severity between groups and also prevented an angiosome-based analysis. There is also potential for bias between surgeons with regard to indications that guide the choice of bypass or endovascular intervention for a given patient; however, the collaborative nature of our practice likely limits this effect. Finally, our institution sees patients from a large catchment area, and patients may have had additional procedures or follow-up at outside institutions that were not documented in our electronic record.
Despite these limitations, this study does give some guidance in the treatment of patients with ischemic tissue loss and tibial arterial disease. Future work may further delineate the role of more advanced endovascular therapies and identify more specific populations of patients that will benefit from one treatment modality over the other. Ultimately, prospective studies comparing open surgical and endovascular revascularization will aid in directing the treatment of tibial arterial disease.
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CONCLUSIONS
In patients with ischemic foot ulcerations and tibial arterial disease, endovascular intervention provides wound healing, amputation, and secondary patency rates that are comparable to those of surgical bypass to an inframalleolar target, despite a disadvantage in primary patency. Endovascular intervention is associated with fewer perioperative complications than pedal bypass. In poor surgical candidates or patients lacking adequate bypass conduit, endovascular tibial intervention is a viable alternative that offers similar limbrelated clinical outcomes. 
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